{"id":"irinotecan-carboplatin-erbitux","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Irinotecan","action":"Monitor","effect":"Increased risk of neutropenia and thrombocytopenia"},{"drug":"Carboplatin","action":"Monitor","effect":"Increased risk of nephrotoxicity"},{"drug":"Irinotecan","action":"Monitor","effect":"Increased risk of diarrhea"},{"drug":"Carboplatin","action":"Monitor","effect":"Increased risk of ototoxicity"},{"drug":"Erbitux (Cetuximab)","action":"Monitor","effect":"Increased risk of infusion reactions"},{"drug":"Irinotecan","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Carboplatin","action":"Monitor","effect":"Increased risk of myelosuppression"},{"drug":"Erbitux (Cetuximab)","action":"Monitor","effect":"Increased risk of dermatologic reactions"},{"drug":"Irinotecan","action":"Monitor","effect":"Increased risk of gastrointestinal toxicity"},{"drug":"Carboplatin","action":"Monitor","effect":"Increased risk of pulmonary toxicity"},{"drug":"Erbitux (Cetuximab)","action":"Monitor","effect":"Increased risk of cardiac dysfunction"}],"commonSideEffects":[],"contraindications":["Contraindication or intolerance to a generically available agent/regimen (e.g., cisplatin- or carboplatin-based regimens, docetaxel, etc.)","Contraindication or intolerance to pembrolizumab/(cisplatin or carboplatin)/5-FU","Contraindication or intolerance to one of the following regimens: Pembrolizumab/(cisplatin or carboplatin)/5-FU"],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"Children with refractory solid tumors, ages 1 to 18 years","Renal impairment":"No information available","Hepatic impairment":"No information available"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=irinotecan-carboplatin-erbitux","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:55:04.845680+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:55:10.494948+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:55:04.919118+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=irinotecan-carboplatin-erbitux","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:55:10.794327+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:55:11.831718+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1351/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:55:11.498129+00:00"}},"allNames":"irinotecan + carboplatin + erbitux","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Irinotecan-carboplatin-erbitux is a chemotherapy combination marketed by Pfizer Inc. It targets various molecular pathways to treat different types of cancer. The combination is used for first-line treatment of squamous cell carcinoma of the head and neck, recurrent or metastatic SCCHN, and metastatic colorectal cancer. It has shown clinical differentiation in patients who have failed previous treatments. The commercial significance of irinotecan-carboplatin-erbitux is substantial, with $21.2B in revenue. There are no notable pipeline developments for this drug.","brandName":"irinotecan + Carboplatin + erbitux","ecosystem":[],"isGeneric":true,"mechanism":{"target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","novelty":"best-in-class","modality":"small molecule, monoclonal antibody","drugClass":"chemotherapy","explanation":"","oneSentence":"","technicalDetail":"Irinotecan (CPT-11) inhibits topoisomerase I, leading to DNA damage and apoptosis in cancer cells. Carboplatin (CBDCA) forms platinum-DNA adducts, causing DNA damage and cell death. Erbitux (cetuximab) binds to EGFR, preventing its activation and downstream signaling pathways that promote cancer cell growth."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:29:02.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"7","annualCostUS":"$80,000/yr","genericStatus":"Biologic — patent protected","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=irinotecan-carboplatin-erbitux","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=irinotecan-carboplatin-erbitux","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:55:13.117568+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Opdivo (nivolumab)","company":"Bristol-Myers Squibb","advantage":"Immune checkpoint inhibitor used to treat many cancers, including melanoma, lung, liver, etc."},{"name":"Opdivo Qvantig (hyaluronidase / nivolumab)","company":"Bristol-Myers Squibb","advantage":"Immune checkpoint inhibitor used to treat many cancers, including melanoma, lung, liver, etc."},{"name":"Keytruda (pembrolizumab)","company":"Merck & Co.","advantage":"Immune checkpoint inhibitor used to treat many cancers, including melanoma, lung, liver, etc."},{"name":"Keytruda Qlex","company":"Merck & Co.","advantage":"Immune checkpoint inhibitor used to treat many cancers, including melanoma, lung, liver, etc."},{"name":"Pembrolizumab","company":"Merck & Co.","advantage":"Immune checkpoint inhibitor used to treat many cancers, including melanoma, lung, liver, etc."},{"name":"Nivolumab","company":"Bristol-Myers Squibb","advantage":"Immune checkpoint inhibitor used to treat many cancers, including melanoma, lung, liver, etc."},{"name":"Cetuximab","company":"Merck KGaA","advantage":"EGFR inhibitor used to treat colorectal cancer, head and neck cancer, etc."},{"name":"Methotrexate","company":"Various","advantage":"Chemotherapy agent used to treat various cancers, including head and neck cancer, etc."},{"name":"Oxaliplatin","company":"Sanofi","advantage":"Chemotherapy agent used to treat colorectal cancer, etc."},{"name":"Xeloda (capecitabine)","company":"Roche","advantage":"Chemotherapy agent used to treat colorectal cancer, etc."},{"name":"Fluorouracil","company":"Various","advantage":"Chemotherapy agent used to treat colorectal cancer, etc."},{"name":"Wellcovorin (leucovorin)","company":"Pfizer","advantage":"Chemotherapy agent used to treat colorectal cancer, etc."},{"name":"Capecitabine","company":"Roche","advantage":"Chemotherapy agent used to treat colorectal cancer, etc."}],"genericName":"irinotecan-carboplatin-erbitux","indications":{"approved":[{"name":"First-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil and radiation therapy.","regulator":"FDA"},{"name":"Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed oxaliplatin-based chemotherapy.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"},{"name":"Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00248287","phase":"PHASE2","title":"PhII ICb With/Without Erbitux in MBC Pts","status":"ACTIVE_NOT_RECRUITING","sponsor":"US Oncology Research","startDate":"2005-07-28","conditions":"Metastatic Breast Cancer","enrollment":154}],"_emaApprovals":[{"date":"","name":"irinotecan + Carboplatin + erbitux","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL1351"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule, monoclonal antibody","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:55:13.117568+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}